Seaport debuts with $100M Series A, as psychiatric boom grows

The team behind Karuna Therapeutics, which was recently snapped up in a multibillion-dollar deal, on Tuesday rolled out another neuropsychiatric-focused biotech, called Seaport Therapeutics. 

The new company will be led by Daphne Zohar, the founding CEO of the biotech startup foundry PureTech Health, which helped launch both Karuna and Seaport. 

Seaport raised $100 million in a Series A round, with backers including the same investors who initially funded Karuna, namely ARCH Venture Partners, Sofinnova Investments, and Third Rock Ventures.